Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04750785 · ClinicalTrials.gov registry record
A Study to Assess Choroideremia (CHM) Health Outcomes
A clinical trial, sponsored by Biogen.
- Completed
- Registry status
- 46
- Enrollment target
NCT04750785: Completed study, sponsored by Biogen.
NCT04750785 is a clinical trial that has completed, run by Biogen. The registered enrollment target is 46 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04750785 has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- 46 participants
- Enrollment target
Study Summary
The primary objectives of this study are to describe disease progression and severity by age in participants with CHM, to assess health-related quality-of-life, resource utilization and work productivity, and to assess quality-of-life, work productivity, and impact on daily activities in caregivers of participants with CHM at different stages of disease progression.
Interventions
- OTHER No Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2020-12-15 |
| Est. Completion | 2021-09-27 |
What the finished NCT04750785 record still lists
NCT04750785 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 46 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which No Intervention is the first listed.
NCT04750785 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04750785 about?
NCT04750785 is a clinical study titled "A Study to Assess Choroideremia (CHM) Health Outcomes". The primary objectives of this study are to describe disease progression and severity by age in participants with CHM, to assess health-related quality-of-life, resource utilization and work productivity, and to assess quality-of-life, work productivity, and impact on daily activities in caregivers ...
What is the current status of trial NCT04750785?
This trial is currently completed. The enrollment target is 46 participants. The study started on 2020-12-15. Estimated completion is 2021-09-27.
What interventions are being tested in trial NCT04750785?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT04750785?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI